{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:02:46Z","timestamp":1781625766483,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"am","delay-in-days":296,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015060","name":"Nagasaki University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.trim.2025.102262","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T02:44:20Z","timestamp":1750387460000},"page":"102262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Donor lymphocyte infusion-based therapy for relapsed adult T-cell leukemia\/lymphoma after HLA-haploidentical hematopoietic stem cell transplantation"],"prefix":"10.1016","volume":"92","author":[{"given":"Shinichi","family":"Katsuoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Itonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Furumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeharu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Horai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nariyoshi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroo","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2025.102262_bb0005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12185-018-02588-5","article-title":"JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-8. Adult T-cell leukemia-lymphoma","volume":"109","author":"Tsukasaki","year":"2019","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.trim.2025.102262_bb0010","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2403682","article-title":"Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma","volume":"19","author":"Fukushima","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.trim.2025.102262_bb0015","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1182\/bloodadvances.2021004932","article-title":"Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study","volume":"5","author":"Ito","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.trim.2025.102262_bb0020","article-title":"Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia\/lymphoma","author":"Yoshimitsu","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trim.2025.102262_bb0025","doi-asserted-by":"crossref","first-page":"928.e1","DOI":"10.1016\/j.jtct.2021.07.010","article-title":"A phase I\/II multicenter trial of HLA-haploidentical PBSCT with PT-cy for aggressive adult T cell leukemia\/lymphoma","volume":"27","author":"Tanaka","year":"2021","journal-title":"Transplant Cell. Ther."},{"key":"10.1016\/j.trim.2025.102262_bb0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hon.2558","article-title":"The outcome and characteristics of patients with relapsed adult T cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Kato","year":"2019","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.trim.2025.102262_bb0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood-2012-07-444372","article-title":"Treatment of relapsed adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki transplant group experience","volume":"121","author":"Itonaga","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.trim.2025.102262_bb0040","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the lymphoma study group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.trim.2025.102262_bb0045","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan clinical oncology group study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trim.2025.102262_bb0050","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","article-title":"Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting","volume":"27","author":"Tsukasaki","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trim.2025.102262_bb0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3324\/haematol.2019.219790","article-title":"Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT","volume":"105","author":"Dholaria","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.trim.2025.102262_bb0060","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/10428194.2023.2276058","article-title":"RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL","volume":"65","author":"Itonaga","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.trim.2025.102262_bb0065","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/leu.2016.144","article-title":"Loss of the mismatched human leukocyte antigen haplotype in two acute myelogenous leukemia relapses after haploidentical bone marrow transplantation with posttransplantation cyclophosphamide","volume":"30","author":"McCurdy","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.trim.2025.102262_bb0070","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/leu.2014.314","article-title":"Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation","volume":"29","author":"Crucitti","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.trim.2025.102262_bb0075","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.trim.2025.102262_bb0080","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12185-012-1056-3","article-title":"Successful treatment by donor lymphocyte infusion of adult T-cell leukemia\/lymphoma relapse following allogeneic hematopoietic stem cell transplantation","volume":"95","author":"Kamimura","year":"2012","journal-title":"Int. J. Hematol."},{"issue":"34","key":"10.1016\/j.trim.2025.102262_bb0085","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.trim.2025.102262_bb0090","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.trim.2025.102262_bb0095","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s12185-024-03857-2","article-title":"Improved survival among elderly patients with aggressive adult T-cell leukemia\/lymphoma: impact of mogamulizumab-containing chemotherapy","volume":"120","author":"Hashimoto","year":"2024","journal-title":"Int. J. Hematol."},{"issue":"8","key":"10.1016\/j.trim.2025.102262_bb0100","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.trim.2025.102262_bb0105","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hon.3115","article-title":"Lenalidomide treatment for recurrent adult T-cell leukemia\/lymphoma after allogeneic hematopoietic cell transplantation","volume":"41","author":"Tanaka","year":"2023","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.trim.2025.102262_bb0110","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/hon.2712","article-title":"Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki transplant group experience","volume":"38","author":"Sakamoto","year":"2020","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.trim.2025.102262_bb0115","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41409-018-0291-5","article-title":"Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation","volume":"54","author":"Inoue","year":"2019","journal-title":"Bone Marrow Transplant."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327425000905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327425000905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T23:53:00Z","timestamp":1757116380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327425000905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":23,"alternative-id":["S0966327425000905"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2025.102262","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donor lymphocyte infusion-based therapy for relapsed adult T-cell leukemia\/lymphoma after HLA-haploidentical hematopoietic stem cell transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2025.102262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102262"}}